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EDITORIAL
The Importance of Measuring the Measures
Eric Whitacre, MD, FACS
Department of Surgery, The Breast Center of Southern Arizona, Tucson, AZ
‘‘Preoperative Needle Biopsy as a Potential Quality
Measure in Breast Cancer Surgery,’’ by Pocock et al., is a
valuable contribution to our understanding of the role of
preoperative needle biopsy as a quality indicator in breast
surgery. The report is valuable not only because of the
information presented, but also because it demonstrates the
process that should be applied to any proposed quality
measure before it is implemented in clinical practice: First
to develop a hypothesis, then to collect and analyze data,
and then return to the hypothesis with corrections or pro-
posed improvements. In this instance, the authors propose
that preoperative needle biopsy of any suspicious lesions
before breast surgery is a useful quality measure, demon-
strate how this can be applied in clinical practice, then use
their results to formulate a tentative benchmark. Important
practical information about real-world limitations of the
measure are documented, and useful proposals are put forth
to improve the ability to collect data and measure com-
pliance in the future.
Application of the scientific method to the development
and implementation of quality measures is important for
several reasons. First, quality measures are not always what
they seem. The Patient Safety and Quality Committee of the
American Society of Breast Surgeons recently completed a
review of more than 40 proposed quality measures in breast
surgery, including a measure of time from initial diagnosis
of breast cancer to the time of definitive surgical manage-
ment. The survey included 20 surgeons who reported on
more than 60 data elements on up to 20 breast cancer
patients each. Because the surgeons included a group of
dedicated and highly motivated breast specialists, there was
every expectation that the interval from diagnosis to
definitive surgery would be quite short. However, this was
not the case. In fact, there was a wide range (mean ± SD,
30 ± 15 days) (Lorraine Tafra, personal communication).
Surprisingly, most of the ‘‘delays’’ resulted from patient
choice. On review, it was clear that measurement of a
simple time interval was not reflective of quality; instead, it
would have been necessary to measure a combination of
appropriate surgical management and patient choice about
the timing of care.
Collection of clinical performance data is also critical
for development of quality measures, not only to establish
benchmarks but also to show that accurate data retrieval is
feasible in practice. Although preoperative percutaneous
needle biopsy has been recognized as a quality indicator for
many years, remarkably little published information is
available to document the frequency of needle biopsy
compared with open surgical biopsy, or to establish a
benchmark for measurement of clinical performance.1,2
The present study, together with the cited publication by
Lannin et al., constitute the bulk of the peer-reviewed lit-
erature on how frequently needle biopsy can effectively be
performed in clinical practice.3
It is also important to collect data about the measure in
order to understand how to use the information to ensure
quality care. In their mature form, quality measures should
not merely serve as a yardstick of performance, but as a
mechanism to help improve quality. The authors of the
present study propose how other centers can begin to col-
lect information on percutaneous needle biopsy, and they
suggest that the measure is important enough to add as a
separate data field in national databases. Indeed, the pro-
cess of measurement alone should begin to improve
performance.4 This report, from a comprehensive breast
center at a major academic institution, presumably repre-
sents the highest level of performance, with expert imagers
and surgeons working in collaboration to achieve the best
care. However, if a breast center does not meet the pro-
posed benchmark, what are the best corrective measures? A
limitation of the present study is that it does not explain
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how to help other centers achieve such a high level of
compliance.
In addition, the current study presents data that are
interpreted as reflecting the performance at a treatment
center. But isn’t this measure more a reflection of the
performance of individual physicians who practice at a
center? Whether or not the patient is taken to surgery
without first undergoing a needle biopsy is the decision of
the individual surgeon working within the context of
available local resources. In appreciation of these limita-
tions, the authors themselves recognize that ‘‘In order to
better assess the effectiveness of this quality measure, it
would be necessary to design a study across a range of
different institutions and across a broader period of time,
extending beyond a year.’’
To help clarify some of these issues, the American
Society of Breast Surgeons recently announced a pilot
program to collect data on three surgeon-controlled quality
measures, including percutaneous needle biopsy before
open biopsy.5 This program, which is currently open for
enrollment, is a voluntary Web-based reporting tool to
collect information on the following: (1) percutaneous
needle biopsy before open surgery, (2) orientation of the
surgical specimen, and (3) verification that an image-gui-
ded target has been surgically removed.
Although surgeons will have to register for the program,
the data collected are not publicly linked to the individual
surgeon, with the goal being simply to obtain information
about these measures in a wide range of clinical practice. It
consists of simple ‘‘yes/no’’ reporting of the individual
quality measures for each open surgical breast procedure,
with a pull-down list of reasons if the measure was not
performed. With participation of a diverse group of sur-
geons from different practice environments, the program
should obtain information that will eventually allow these
measures to be implemented most effectively. The
National Consortium of Breast Centers has a similar pro-
ject that collects data on percutaneous needle biopsy from
centers rather than individual surgeons.6 Both programms
allow participants to monitor their performance compared
to the larger groups, which should itself result in improved
performance.
In the present environment of proliferating standards
and organizations focusing on quality measurement, the
development of quality measures should be based on data
that demonstrate not only the efficacy of the measure in
assessing quality, but also how the measure can be applied
to improve performance. The development of quality
measures must be distinguished from the process of
defining benchmarks for performance because this requires
a more complete understanding of the complex interaction
of physician judgment, patient choice, and available
resources. In light of demands from insurance plans and the
public, it is understandable that there is a perceived
urgency to implement any widely recognized quality
measures. In an editorial published in 2007, Auerback et al.
warned of the dangers of action over evidence in this arena:
‘‘The temptation is to circumvent traditional models of
evidence when it comes to quality improvement, but this
temptation has always existed in medicine for those seek-
ing cures to conditions with high morbidity. Just as in the
rest of medicine, we must pursue the solution to quality and
safety problems in a way that does not blind us to harms,
squander scare resources, or delude us about the effec-
tiveness of our efforts.’’7 The present study reminds us that
before even the most widely accepted quality measures are
used to assess clinical performance, it is important to begin
by measuring the measures.
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